Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection—comparison with omeprazole and lansoprazole
Authors:
- 1 June 1999
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 13 (6) , 741-746
Abstract
Background: : A recent trend in curative therapy for Helicobacter pylori infection is the so‐called triple therapy, which consists of a proton pump inhibitor (PPI) and two different antimicrobials. Various regimens employing this triple therapy have been reported. However, little is known about the effectiveness of rabeprazole, a recently developed proton pump inhibitor, when used in the triple therapy.Aim: : To validate its usefulness by comparing rabeprazole with omeprazole and lansoprazole, in combination with amoxycillin and clarithromycin.Patients and methods: : 221 H. pylori‐positive patients with peptic ulcer disease were randomized to receive one of three different proton pump inhibitor/amoxycillin–clarithromycin (PPI/AC) regimens for 7 days. (i) OAC regimen (n = 75): omeprazole 20 mg b.d., amoxycillin (AMOX) 500 mg t.d.s. and clarithromycin (CAM) 200 mg b.d.; (ii) LAC regimen (n = 74): lansoprazole 30 mg b.d., AMOX 500 mg t.d.s. and CAM 200 mg b.d.; and (iii) RAC regimen (n = 72): rabeprazole 20 mg b.d., AMOX 500 mg t.d.s. and CAM 200 mg b.d. Cure of the infection was determined by the 13C urea breath test 1 month after completion of the treatment.Results: : Intention‐to‐treat based cure rates for OAC, LAC and RAC regimens were 85% (95% CI, 75–92), 84% (95%, CI 73–91) and 88% (95% CI, 78–94), respectively, and per protocol based cure rates of these regimens were 88% (95% CI, 78–94), 91% (95%, CI 82–99) and 93% (95% CI, 84–98), respectively. Adverse effects in the entire study population, which included diarrhoea, glossitis or skin rash, were reported by 15% of the patients, and complete compliance was achieved in 95% of these patients.Conclusion: : 1‐week proton pump inhibitor/AC regimens for H. pylori infection were effective in the Japanese population. Rabeprazole can be considered as equivalent to omeprazole and lansoprazole in the PPI/AC triple therapy.Keywords
This publication has 24 references indexed in Scilit:
- Efficacy of Lansoprazole in Eradicating Helicobacter pylori: A Meta‐AnalysisHelicobacter, 1998
- Effectiveness of Omeprazole‐Amoxicillin‐Clarithromycin (OAC) Therapy for Helicobacter pylori Infection in a Japanese PopulationHelicobacter, 1998
- Prolonged and Profound Acid Inhibition Is Crucial in Helicobacter pylori Treatment with a Proton Pump Inhibitor Combined with AmoxicillinScandinavian Journal of Gastroenterology, 1998
- RabeprazoleDrugs, 1998
- Effect of Fasting Subjects’ Posture on 13C‐Urea Breath Test for Detection of Helicobacter pylori InfectionHelicobacter, 1997
- Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the ratGastroenterology, 1997
- Randomized comparison of differing periods of twice‐a‐day triple therapy for the eradication of Helicobacter pyloriAlimentary Pharmacology & Therapeutics, 1996
- The effect of environmental pH on the proton motive force of Helicobacter pyloriGastroenterology, 1996
- Pharmacokinetics, Metabolism and Interactions of Acid Pump InhibitorsClinical Pharmacokinetics, 1996
- The Role of Omeprazole and Antibiotic Combinations in the Eradication ofHelicobacter pylori—An UpdateScandinavian Journal of Gastroenterology, 1994